Vertex Pharmaceuticals made headlines with a 14% share price jump, despite an overall market dip, thanks to clinical wins and ...

Vertex Pharmaceuticals (NasdaqGS:VRTX) saw its share price rise by approximately 14% in the last quarter, a significant move considering the broader market's recent 1% decline. The company's legal ...

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted regulatory approval for a label expansion of KAFTRIO ® (ivacaftor ...

What should investors who are experiencing Nasdaq market whiplash do now? I think buying three Nasdaq stocks hand over fist and holding them for decades is a smart move.

However in 2020, she received a life-changing cystic fibrosis drug called Kaftrio, which transformed her life and drastically ...

A Scottish cystic fibrosis patient who wrote goodbye letters to her family before a revolutionary drug saved her life has ...

The new approval makes the regimen an option for around 4,000 patients in the EU who have at least one non-class I CFTR mutation.

Vertex Pharmaceuticals VRTX announced that the European Commission (EC) has expanded the label of its blockbuster cystic ...

Vertex Pharmaceuticals VRTX announced that the European Commission (EC) has expanded the label of its blockbuster cystic fibrosis (CF) drug, Kaftrio, to treat all patients aged two years and older ...

(RTTNews) - Vertex Pharmaceuticals (VRTX) announced that the European Commission has approved a label expansion for KAFTRIO (ivacaftor/tezacaftor/elexacaftor) in ...